Prospective Comparison of Hemorrhagic Complications After Treatment With Enoxaparin
|
|
- Elaine Shelton
- 6 years ago
- Views:
Transcription
1 Prospective Comparison of Hemorrhagic Complications After Treatment With Versus Unfractionated Heparin for Unstable Angina Pectoris or Non ST-Segment Elevation Acute Myocardial Infarction Scott D. Berkowitz, MD, Sandra Stinnett, PhD, Marc Cohen, MD, Gregg J. Fromell, MD, and Frederique Bigonzi, MD, on behalf of the ESSENCE Investigators* Patients with unstable angina pectoris (UAP) or non STsegment elevation acute myocardial infarction (AMI) are at risk of death or recurrent ischemic events, despite receiving aspirin and unfractionated heparin (). This study investigates the effect of the low molecular weight heparin, enoxaparin, on the incidence of hemorrhage and thrombocytopenia in relation to baseline characteristics and subsequent invasive procedures. Rates of hemorrhage and thrombocytopenia were analyzed for UAP or non ST-segment elevation AMI in patients included in the prospective, randomized, double-blind Efficacy and Safety of Subcutaneous in Non Q-wave Coronary Events (ESSENCE) study. Patients received either enoxaparin or, plus aspirin, for 2 to 8 days. The overall rate of major hemorrhage (at 30 days) was comparable between the 2 groups (6.5% for enoxaparin vs 7.0% for, p 0.6). The rate of major hemorrhage while on treatment was slightly higher in the enoxaparin group, but this was not significant (1.1% vs A number of studies have investigated low molecular weight heparins as an alternative to unfractionated heparin () in the management of unstable angina pectoris (UAP) or non ST-segment elevation acute myocardial infarction (AMI). 1 9 The Efficacy and Safety of Subcutaneous in Non Qwave Coronary Events (ESSENCE) study found a significant reduction in acute coronary events in patients with UAP or non Q-wave myocardial infarction treated with subcutaneous enoxaparin in comparison with intravenous. 4 However, concerns about the From the Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina; MCP Hahnemann University School of Medicine, Philadelphia, Pennsylvania; Aventis Pharma, Paris, France; and AstraZeneca, Wayne, Pennsylvania. This study and Dr. Cohen were supported by a grant from Aventis Pharma, Paris, France. Manuscript received May 31, 2001; revised manuscript received and accepted July 26, Address for reprints: Marc Cohen, MD, Cardiac Catheterization Lab, Mail Stop 119, Hahnemann University Hospital, Philadelphia, Pennsylvania marc.cohen@tenethealth.com *A list of the ESSENCE investigators can be found in N Engl J Med 1997;337: % for, p 0.204), as was the rate of major hemorrhage within 48 hours of coronary artery bypass grafting performed within 12 hours of treatment. However, the rate of minor hemorrhage was significantly higher in the enoxaparin group, with the majority being injection-site ecchymoses or hematomas (11.9% vs 7.2% with, p <0.001). Thrombocytopenia (platelet count <100,000 per mm 3 ) occurred mainly in association with coronary bypass surgery, with a similar rate in both groups. Thus, enoxaparin is a well-tolerated alternative to in the management of UAP or non ST-segment elevation AMI. Despite the more effective antithrombotic effect, which results in fewer ischemic events, enoxaparin is not associated with an increase in the rate of major hemorrhagic complications, and is not significantly associated with thrombocytopenia, but is associated with an increase in minor injection site ecchymosis by Excerpta Medica, Inc. (Am J Cardiol 2001;88: ) safety of antithrombotic treatment of UAP and/or non ST-segment elevation AMI are of paramount importance, particularly in view of the frequent requirement for invasive coronary revascularization procedures in patients with these syndromes, and of previous reviews comparing rates of bleeding observed with low molecular weight heparin The present study provides further details of the hemorrhagic events and development of thrombocytopenia in the ESSENCE trial, in which 32% of the patient cohort had revascularization procedures within the first 30 days. METHODS Patient population and treatment protocol: Full details of the ESSENCE study have been described previously in detail. 4 The ESSENCE study was a prospective, randomized, double-blind, parallel-group multicenter trial in patients with recent-onset angina at rest with additional evidence of underlying ischemic heart disease. All patients received aspirin, and were randomly assigned for 2 to 8 days to either enoxaparin 1 mg/kg administered subcutaneously every 12 hours, or a 5,000 U intravenous bolus of followed by a by Excerpta Medica, Inc. All rights reserved /01/$ see front matter The American Journal of Cardiology Vol. 88 December 1, 2001 PII S (01)
2 TABLE 1 Baseline Characteristics and Risk Factors of Patients With Major and Minor Bleeding (all-treated population) Major Bleeding Minor Bleeding Characteristic All-Treated Population (n 102) (n 107) (n 206) (n 128) Sex Men 2064 (66%) 72 (71%) 63 (59%) 121 (59%) 72 (56%) Women 1,043 (34%) 30 (29%) 44 (41%) 85 (41%) 56 (44%) Race Non-white 314 (10%) 6 (6%) 11 (10%) 14 (7%) 13 (10%) White 2,793 (90%) 96 (94%) 96 (90%) 192 (93%) 115 (90%) Age (yrs) Mean SD Median (25th 75th percentile) 65 (55 72) 68 (61 73) 66 (57 72) 65 (56 73) 68 (58 75) Weight (kg) Mean SD Median (25th 75th percentile) 78 (64 88) 80 (68 89) 77 (68 88) 79 (70 89) 77 (64 89) Body surface area (m 2 ) Mean SD Median (25th 75th percentile) 1.88 ( ) 1.92 ( ) 1.88 ( ) 1.89 ( ) 1.86 ( ) Smoker Current 748 (24%) 16 (16%) 22 (21%) 41 (20%) 23 (18%) Previous 268 (9%) 12 (12%) 6 (6%) 18 (9%) 8 (6%) Never 2,091 (67%) 74 (73%) 82 (77%) 147 (71%) 97 (76%) Obese 1,560 (50%) 45 (45%) 55 (51%) 108 (53%) 68 (53%) Prior aspirin use 1,926 (62%) 67 (66%) 72 (67%) 122 (60%) 84 (66%) Initial ECG changes 1,760 (57%) 67 (66%) 69 (65%) 120 (58%) 77 (60%) Final admission diagnosis Unstable angina 2,157 (69%) 65 (64%) 67 (63%) 144 (71%) 85 (67%) Non Q-wave MI 645 (21%) 31 (31%) 38 (36%) 40 (20%) 38 (30%) Q-wave MI 101 (3%) 3 (3%) 2 (2%) 6 (3%) 2 (2%) Creatinine clearance (mg/dl) Mean SD Median (25th 75th percentile) 77 (58 99) 77 (55 95) 76 (56 97) 80 (57 98) 68 (53 96) ECG electrocardiogram; obese body mass index of 26.9 kg/m 2 for women, 27.2 kg/m 2 for men. continuous infusion adjusted to the activated partial thromboplastin time (target range 55 to 85 seconds). The primary efficacy end point was the composite triple end point of death, myocardial infarction, and recurrent angina at the 14-day follow-up visit. If patients underwent coronary bypass surgery during the study, the patients randomized to receive enoxaparin may have been given additional (but no additional enoxaparin) during surgery. Safety end points: The primary safety end point was the incidence of hemorrhagic episodes by day 30 in the ESSENCE trial. Secondary safety analyses included the incidence of hemorrhagic episodes on treatment, defined as up to 2 hours after the end of the intravenous infusion for patients who received or within 12 hours of the last subcutaneous dose for patients treated with enoxaparin. Only adjudicated hemorrhagic events (subject to clinical events committee adjudication) are presented in this study. Major hemorrhage was defined as clinically overt bleeding associated with 1 of the following: death; transfusion of 2 U of packed red cells or whole blood; a decrease in hemoglobin levels of 30 g/l (1.9 mmol/l); and retroperitoneal, intracranial, or intraocular hemorrhage. Minor hemorrhage was defined as any clinically important bleeding that did not qualify as major hemorrhage. Platelet counts were performed on blood collected in ethylenediaminetetraacetic acid before randomization, on day 3 ( 1 day), and at the end of treatment ( 1 day). Moderate thrombocytopenia was defined as a nadir platelet count of 100,000/mm 3, and severe thrombocytopenia was defined as a nadir platelet count of 50,000/mm 3. Statistical analysis: The safety analyses for this study were performed on the all-treated population only (i.e., those patients who received 1 dose of trial drug). Hemorrhagic events were analyzed by incidence, severity, causality, consequences, and association with percutaneous coronary interventions. Subgroup analyses according to certain demographic and baseline variables were undertaken to ascertain correlates of bleeding complications. Pearson s chi-square tests were used to compare the impact of the different antithrombotic trial drugs on the changes in platelet count and hemoglobin during the 30-day period. All comparisons were 2-tailed statistical tests at a 5% significance level. RESULTS In the ESSENCE trial, 3,171 patients were randomized. A total of 3,107 patients received 1 dose of study treatment and were included in the present safety analyses. Baseline characteristics and use of nonstudy anticoagulants, aspirin, or other antiplatelet medications in the week before randomization were similar for both the enoxaparin and treatment groups (Table 1); both study drugs were administered for a median duration of 2.6 days. CORONARY ARTERY DISEASE/HEMORRHAGIC COMPLICATIONS AFTER ENOXAPARIN AND HEPARIN 1231
3 TABLE 2 Summary of Hemorrhagic Events at 30 Days (all-treated population) p Value Any major hemorrhage* 209 (6.7%) 102 (6.5%) 107 (7.0%) NS While on treatment 27 (0.9%) 17 (1.1%) 10 (0.7%) NS Associated with coronary bypass 159 (5.1%) 75 (4.8%) 84 (5.5%) NS Not associated with coronary bypass 50 (1.6%) 27 (1.7%) 23 (1.5%) Causing death 1 (0.03%) 0 1 (0.1%) NS Drop in hemoglobin 30 g/l (1.9 mmol/l) 159 (5.1%) 77 (4.9%) 82 (5.4%) NS Drop in hemoglobin 50 g/l loss 124 (3.9%) 58 (3.7%) 66 (4.3%) NS Resulted in transfusion 2 U of blood 167 (5.4%) 83 (5.3%) 84 (5.5%) NS Retroperitoneal, intracranial, or intraocular 3 (0.1%) 1 (0.1%) 2 (0.1%) NS Any minor hemorrhage (only) 298 (9.6%) 188 (11.9%) 110 (7.2%) Drug discontinued 53 (1.7%) 28 (1.8%) 25 (1.6%) NS Required transfusion ( 2 U of blood) 12 (0.4%) 5 (0.3%) 7 (0.5%) NS Serious as per investigator 13 (0.4%) 5 (0.3%) 8 (0.5%) Injection-site ecchymosis 132 (4.2%) 102 (6.5%) 30 (2.0%) Non injection-site ecchymosis 55 (1.8%) 31 (2.0%) 24 (1.6%) Any hemorrhage While on treatment 507 (16.3%) 290 (18.4%) 217 (14.2%) Leading to study drug discontinuation 216 (7.0%) 148 (9.4%) 68 (4.4%) Requiring transfusion ( 2 U of blood) 75 (2.4%) 43 (2.7%) 32 (2.1%) Causality* 195 (6.3%) 95 (6.0%) 100 (6.5%) Spontaneous 127 (4.1%) 77 (4.9%) 50 (3.3%) Secondary to surgery/instrumentation 387 (12.5%) 216 (13.7%) 171 (11.2%) Secondary to other trauma 21 (0.7%) 16 (1.0%) 5 (0.3%) *Subcategories are not mutually exclusive. Hemorrhagic events: Hemorrhagic events by 30 days are summarized in Table 2. At 30 days, the frequency of major hemorrhage was similar in both treatment groups. Some kind of hemorrhagic event (major or minor) occurred in a total of 507 patients (16%). The frequency of any hemorrhage was higher in the enoxaparin group compared with patients treated with. However, the difference in the hemorrhagic rate was a result of the higher number of minor hemorrhagic events in the enoxaparin group. These excess minor events were primarily injectionsite ecchymoses 5 cm in diameter and injection site hematoma 5 cm in diameter. Causality and outcome of hemorrhage:, 387 of 507 hemorrhagic events (76%) and 185 of 209 major hemorrhagic events (89%) were secondary to coronary bypass or percutaneous coronary intervention. Of all the major hemorrhagic events, 159 of 209 (76%) were associated with coronary artery bypass grafting. The incidence of major hemorrhage associated with coronary bypass was equivalent for both groups, and there was no difference between the groups in the outcome and type of major hemorrhage (Table 2). One instance of intracranial hemorrhage and 1 fatal major hemorrhage occurred, both in patients receiving. Hemorrhagic events by subgroup: Major hemorrhagic episodes by treatment, according to predefined potential baseline risk factors, can be found in Table 1. The overall frequency of hemorrhage varied substantially by continent and country, from the highest in South America (31%) to the lowest in Europe (8%). Further analysis of the subgroups revealed that major hemorrhage was more common in patients with renal impairment (defined as creatinine clearance 30 mg/ ml) treated with enoxaparin (4 of 28 enoxaparintreated patients with renal impairment had a major hemorrhage [14%] compared with 2 of 31 patients treated with [6%]). However, the small number of patients in this subgroup prevents firm conclusions being drawn from this finding., compared with all patients, patients with major hemorrhagic events tended to be slightly older. No differences were observed between patients with or without hemorrhage in terms of the maximum activated partial thromboplastin times measured before the hemorrhagic event in the group: the maximum activated partial thromboplastin time value before hemorrhage was 104 seconds, compared with the median value of 101 seconds in patients who did not experience hemorrhaging. Timing of hemorrhagic events and relation to invasive procedures: Of the 507 patients who experienced any hemorrhagic events within the first 30 days, 216 (43%) did so while on study treatment (Table 3). The total incidence of hemorrhage on treatment was higher in the enoxaparin group compared with the group (9.4% vs 4.4%, p 0.001), although the frequency of major hemorrhage while on treatment was comparable for the 2 groups (1.1% vs 0.7%, respectively, p 0.204). More patients in the group required invasive procedures during the study compared with the enoxaparin group (Table 4). A total of 144 patients underwent percutaneous coronary intervention within 12 hours of cessation of treatment; 7 of these patients experienced major hemorrhage. Fifteen of the 31 patients who underwent coronary bypass within 12 hours of cessation of treatment had major hemorrhage. Hematologic parameters: A total of 159 patients (5%) had 1 hemoglobin value that represented a decrease from baseline of 30 g/l (1.9 mmol/l) 1232 THE AMERICAN JOURNAL OF CARDIOLOGY VOL. 88 DECEMBER 1, 2001
4 TABLE 3 Summary of Adjudicated Hemorrhagic Event Incidence While on Study Medication (all-treated population) during the 30-day period. There were no statistically significant differences between treatments for changes in this value. Moderate thrombocytopenia (platelet count 100,000/mm 3 ) was similar for the 2 treatment groups (Table 5). The overall incidence of severe thrombocytopenia (platelet count 50,000/mm 3 )was 0.5%, and this event was most commonly associated with coronary bypass; no treatment differences were observed. Moderate thrombocytopenia was associated with a significantly higher risk of adverse clinical outcomes, including acute cardiac events, requirement for percutaneous procedures, major hemorrhage, major hemorrhage associated with coronary bypass, requirement for transfusion, and a decrease in hemoglobin of 30 g/l (p for all comparisons vs patients without thrombocytopenia). DISCUSSION The present study provides evidence, based on a blinded, randomized comparison, that enoxaparin is at least as safe as (with regard to major hemorrhage) in the management of UAP or non ST-segment Any major hemorrhage 27 (0.9%) 17 (1.1%) 10 (0.7%) Associated with coronary bypass 6 (0.2%) 4 (0.3%) 2 (0.1%) Causing death Drop in hemoglobin 30 g/l 16 (0.5%) 9 (0.6%) 7 (0.5%) Resulted in transfusion (with 2 U of blood) 21 (0.7%) 13 (0.8%) 8 (0.5%) Retroperitoneal, intracranial, or intraocular 1 (0.0%) 1 (0.1%) 0 Any hemorrhage 216 (7.0%) 148 (9.4%) 68 (4.4%) Leading to study drug discontinuation 69 (2.2%) 38 (2.4%) 31 (2.0%) Requiring transfusion (with 2 U of blood) 28 (0.9%) 16 (1.0%) 12 (0.8%) Causality* Spontaneous 83 (2.7%) 58 (3.7%) 25 (1.6%) Secondary to surgery/instrumentation 126 (4.1%) 86 (5.4%) 40 (2.6%) Secondary to other trauma 16 (0.5%) 13 (0.8%) 3 (0.2%) *Subcategories are not mutually exclusive. p 0.204; p TABLE 4 Hemorrhagic Events Within 48 Hours of Intervention in Patients Who Underwent Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting Within 12 Hours of Cessation of Treatment Patients undergoing coronary intervention 529 (17%) 236 (15%) 293 (19%) up to day 30 (n)* Coronary intervention within 12 h of 144 (4.5%) 60 (3.7%) 84 (5.4%) cessation of treatment Major hemorrhage within 48 h after 7 (4.9%) 4 (6.7%) 3 (3.6%) coronary intervention (within 12 h of cessation of treatment) Patients undergoing coronary bypass 412 (13%) 198 (12%) 214 (14%) Coronary bypass within 12 h of 31 (1.0%) 9 (0.6%) 22 (1.4%) cessation of treatment Major hemorrhage within 48 h after coronary bypass (within 12 h of cessation of treatment) 15 (48%) 5 (56%) 10 (46%) *p 0.002; p elevation AMI. Although the likelihood of any hemorrhagic event in the ESSENCE study was greater for enoxaparin-treated patients compared with -treated patients, the increase was almost wholly accounted for by a higher rate of minor hemorrhagic events, mainly injection site ecchymosis and hematoma. The incidence of major hemorrhage were similar for both treatment groups at 30 days, but was slightly higher in the enoxaparin group while on treatment, but not significantly so, as were the rate of blood transfusion and significant decreases in hemoglobin. It should be noted that in this study the definition of major hemorrhage was quite wide, including retroperitoneal hemorrhage and transfusion and a decrease in hemoglobin content of 30 g/l. Most hemorrhagic events occurred within the context of surgery or percutaneous coronary intervention, with similar numbers in the enoxaparin and groups having major hemorrhage related to coronary bypass. Similarly, noncoronary bypass related bleeding occurred at similar rates in the 2 treatment groups. The effect of anticoagulant therapy on bleeding associated with cardiac interventions is of considerable clinical importance, given the high frequency of percutaneous interventions following initial medical management of UAP and/or non ST-segment elevation AMI. 10,11 Fewer patients in the enoxaparin group required revascularization procedures up to day 30. The number of patients with major hemorrhage in the 48 hours after a percutaneous coronary intervention or coronary artery bypass grafting procedure performed within 12 hours of cessation of treatment was similar for patients receiving enoxaparin or, although the number of patients in each group was very small, due in part to the protocol recommendation that no revascularization procedures be performed within 48 hours of study treatment unless clinically indicated. For patients who underwent percutaneous coronary intervention or coronary bypass within 12 hours of treatment, the study protocol permitted the use of extra during the procedure in the enoxaparintreated patients, exposing these patients to a higher level of anticoagulant therapy. The increasing use of percutaneous coronary intervention in patients with UAP or non ST-segment elevation AMI has led to clinical studies to assess the safety of enoxaparin during percutaneous coronary intervention, and it has been shown that enoxaparin used as the only anticoagulant appears to be safe and effective. 13 Recently, a CORONARY ARTERY DISEASE/HEMORRHAGIC COMPLICATIONS AFTER ENOXAPARIN AND HEPARIN 1233
5 TABLE 5 Platelet Counts and Hemoglobin Levels During Treatment and Follow-Up (all-treated population) small single-center study investigated the affects of dalteparin 120 U/kg, administered twice daily subcutaneously, on bleeding following coronary bypass in patients with unstable angina. 14 Patients who received a dose of dalteparin within the 12 hours before surgery had a significantly greater blood loss (p 0.001) and increased need for blood transfusion (p 0.047) than patients who received intravenous, who underwent elective coronary bypass, or who last received dalteparin 12 hours before surgery Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26: Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347: Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease (FRIC) study. Circulation 1997;96: p Value Over 30-day period Nadir platelet counts* 50,000/mm 3 16 (0.5%) 7 (0.4%) 9 (0.6%) ,000/mm 3 95 (3.1%) 43 (2.7%) 52 (3.4%) % decrease from baseline 110 (3.5%) 48 (3.0%) 62 (4.0%) On study medication Nadir platelet counts* 50,000/mm 3 2 (0.1%) 2 (0.1%) ,000/mm 3 15 (0.5%) 9 (0.6%) 6 (0.5%) % decrease from baseline 10 (0.3%) 8 (0.5%) 2 (0.1%) *Subcategories are mutually exclusive. On study medication defined as within 2 hours after discontinuation of heparin infusion, or within 12 hours after last enoxaparin injection. 4. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of lowmolecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337: FRAXiparine in Ischaemic Syndrome (FRAXIS) Investigators. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-q wave myocardial infarction. Eur Heart J 1999;20: FRagmin, and Fast Revascularisation during InStability in Coronary artery disease Investigators. Longterm low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354: Antman E, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. prevents death and cardiac ischemic events in unstable angina/non-q-wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B trial. Circulation 1999;100: Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-q wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100: Goodman S, Cohen M, Bigonzi F, Gurfinkel EP, Radley DR, Le Louer V, Fromell GJ, Demers C, Turpie AG, Califf RM, Fox KA, Langer A, for the ESSENCE (Efficacy and Safety of Subcutaneous in Non-Q wave Coronary Events) Study Group. Randomized trial of low molecular weight heparin (enoxaparin) versus heparin for unstable coronary disease: one-year results of the ESSENCE study. J Am Coll Cardiol 2000;36: The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-q-wave myocardial infarction: Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation 1994;89: FRagmin, and Fast Revascularisation during InStability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomised multicentre study. Lancet 1999;354: Thomas DP. Does low molecular weight heparin cause less bleeding? Thromb Haemost 1997;78: Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, Sotirov I, Thomas D. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103: Clark SC, Vitale N, Zacharias J, Forty J. Effect of low molecular weight heparin (fragmin) on bleeding after cardiac surgery. Ann Thorac Surg 2000;69: THE AMERICAN JOURNAL OF CARDIOLOGY VOL. 88 DECEMBER 1, 2001
Inter-regional differences and outcome in unstable angina
European Heart Journal (2000) 21, 1433 1439 doi:10.1053/euhj.1999.1983, available online at http://www.idealibrary.com on Inter-regional differences and outcome in unstable angina Analysis of the International
More informationFissuring of atherosclerotic plaque triggers thrombus formation and is the
New advances in the management of acute coronary syndromes: 4. Low-molecular-weight heparins Walter Ageno, * Alexander G.G. Turpie The case Mr. K, a 57-year-old man, presents to the emergency department
More informationPercutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris
Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris J.Ph. Collet, MD, PhD; G. Montalescot, MD, PhD; L. Lison, MD; R. Choussat, MD; A.
More informationAcute coronary syndrome (ACS) is an
OVERVIEW OF MEDICAL MANAGEMENT OF ACUTE CORONARY SYNDROMES Robert B. Parker, PharmD * Acute coronary syndrome (ACS) is an umbrella term used to describe any group of symptoms of acute myocardial ischemia
More informationQUT Digital Repository:
QUT Digital Repository: http://eprints.qut.edu.au/ This is the author s version of this journal article. Published as: Doggrell, Sheila (2010) New drugs for the treatment of coronary artery syndromes.
More informationJournal of the American College of Cardiology Vol. 35, No. 7, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 7, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00684-3 REVIEW
More informationThe Role of Low-Molecular-Weight Heparin in the Management of Acute Coronary Syndromes
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02901-7
More informationAnticoagulation therapy in acute coronary syndromes according to current guidelines
Acute management of ACS Anticoagulation therapy in acute coronary syndromes according to current guidelines Marcin Grabowski, Marcin Leszczyk, Andrzej Cacko, Krzysztof J. Filipiak, Grzegorz Opolski 1 st
More informationClinical Investigation and Reports
Clinical Investigation and Reports Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin Sonia S. Anand, MD,
More informationA Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS
Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in
More informationPlatelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes
European Heart Journal (00) 3, 1441 1448 doi:10.1053/euhj.00.3160, available online at http://www.idealibrary.com on Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes Gradient of benefit
More informationJournal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early
More informationThe Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial
Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non ST-Elevation Acute Coronary Syndrome The Clopidogrel in Unstable angina to prevent
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin, 250mg powder for concentrate for solution for injection or infusion (Angiox ) No. (516/08) The Medicines Company UK Ltd 07 November 2008 The Scottish Medicines
More informationReview Arterial indications for the low molecular weight heparins Walter Ageno* and Menno V Huisman
Review Arterial indications for the low molecular weight heparins Walter Ageno* and Menno V Huisman *University of Insubria, Varese, Italy Department of General Internal Medicine, Leiden University Medical
More informationPatient characteristics Intervention Comparison Length of followup
ANTICOAGULANT CHAPTER Low Molecular Weight Heparins compared with Unfractionated Heparin Ref ID: 1903 Reference Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic
More informationA Unique, Low Dose of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention
Journal of the American College of Cardiology Vol. 40, No. 11, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02531-7
More informationOtamixaban for non-st-segment elevation acute coronary syndrome
Otamixaban for non-st-segment elevation acute coronary syndrome September 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationNOVEL ANTI-THROMBOTIC THERAPIES FOR ACUTE CORONARY SYNDROME: DIRECT THROMBIN INHIBITORS
Judd E. Hollander, MD Professor, Clinical Research Director, Department of Emergency Medicine University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania OBJECTIVES: 1. Discuss the concept
More informationS PECIAL A RTICLE. Combination Antiplatelet Therapy: Implications for Pharmacists
S PECIAL A RTICLE Combination Antiplatelet Therapy: Implications for Pharmacists Robert L. Talbert, Pharm.D., FCCP, Sarah A. Spinler, Pharm.D., FCCP, Jean M. Nappi, Pharm.D., FCCP, and Michael B. Bottorff,
More informationTitle: Low Molecular Weight Heparins (LMWH), fondaparinux (Arixtra)
Origination: 03/29/05 Revised: 09/01/10 Annual Review: 11/20/13 Purpose: To provide guidelines and criteria for the review and decision determination of requests for medications that requires prior authorization.
More informationThe Thrombolysis In Myocardial Infarction Risk Score in Unstable Angina/ Non ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)03019-x
More informationCase Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA
Case Study 50 YEAR OLD MALE WITH UNSTABLE ANGINA Case History A 50-year-old man with type 1 diabetes mellitus and hypertension presents after experiencing 1 hour of midsternal chest pain that began after
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationJournal of the American College of Cardiology Vol. 37, No. 4, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 37, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01143-3 Acute
More informationTHE INCITING EVENT IN AN ACUTE
CLINICAL CARDIOLOGY Use of Low-Molecular-Weight Heparins in the Management of Acute Coronary Artery Syndromes and Percutaneous Coronary Intervention Graham C. Wong, MD Robert P. Giugliano, MD, SM Elliott
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationJournal of the American College of Cardiology Vol. 49, No. 23, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 49, No. 23, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.01.093
More informationIN patients with ST elevated myocardial infarction, ST segment resolution following
The Effect of Tirofiban on ST Segment Resolution in Patients With Non-ST Elevated Myocardial Infarction Özgür BAYTURAN, 1 MD, Ali Riza BILGE, 1 MD, Cevad SEKÜRI, 1 MD, Ozan ÜTÜK, 1 MD, Hakan TIKIZ, 1 MD,
More informationUse of Anticoagulant Agents and Risk of Bleeding Among Patients Admitted With Myocardial Infarction
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 11, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.08.015 CLINICAL RESEARCH
More information2003 by the American College of Cardiology Foundation ISSN /03/$30.00
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. PII S0735-1097(02)02688-8
More informationRandomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction
Randomized Comparison of Prasugrel and Bivalirudin versus Clopidogrel and Heparin in Patients with ST-Segment Elevation Myocardial Infarction The Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4
More informationCLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA
RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA Dr Lincoff is an interventional cardiologist and the Vice Chairman for Research
More informationOriginal Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice
Am J Cardiovasc Dis 2012;2(3):248-252 www.ajcd.us /ISSN:2160-200X/AJCD1204002 Original Article Impact of timing to coronary angiography in acute coronary syndrome on contemporary clinical practice Angela
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
Economic consequences of routine coronary angiography in low- and intermediate-risk patients with unstable angina pectoris Desai A S, Solomon D H, Stone P H, Avorn J Record Status This is a critical abstract
More informationHuimin Xu 1, Hongwen Cai 2, Zhongshu Qian 1, Geng Xu 3, Xiaofeng Yan 1 and Haibin Dai 1*
Xu et al. BMC Cardiovascular Disorders 2012, 12:118 RESEARCH ARTICLE Open Access Dosing practice of low molecular weight heparins and its efficacy and safety in cardiovascular inpatients: a retrospective
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More informationScottish Medicines Consortium
Scottish Medicines Consortium bivalirudin 250mg for injection or infusion (Angiox ) (156/05) Nycomed UK Ltd No. 4 February, 2005 The Scottish Medicines Consortium has completed its assessment of the above
More informationNovel Risk Markers in ACS (Hyperglycemia, Anemia, GFR)
Novel Risk Markers in ACS (Hyperglycemia, Anemia, GFR) Shaul Atar, MD Department of Cardiology Faculty of Medicine of the Galilee Western Galilee Medical Center, Nahariya, Israel TIMI Risk Score Age 65
More informationOpinion 15 May ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/10 (CIP: )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/10 (CIP: 34009 563 619 7 7) Applicant:
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationPharmacological and Clinical Evidence for the Use of Low- Molecular-Weight Heparins in Acute Coronary Syndromes
Rosito et al Updade Arq Bras Cardiol Pharmacological and Clinical Evidence for the Use of Low- Molecular-Weight Heparins in Acute Coronary Syndromes Guido Aranha Rosito, Otávio Berwanger da Silva, Jorge
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationFFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators
FFR-guided Complete vs. Culprit Only Revascularization in AMI Patients Ki Hong Choi, MD On Behalf of FRAME-AMI Investigators Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, Republic of
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationTIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
European Heart Journal (2005) 26, 865 872 doi:10.1093/eurheartj/ehi187 Clinical research TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS
More informationClopidogrel Date: 15 July 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationThe restoration of coronary flow after an
Pharmacological Reperfusion in Acute Myicardial Infarction after ASSENT 3 and GUSTO V [81] DANIEL FERREIRA, MD, FESC Serviço de Cardiologia, Hospital Fernando Fonseca, Amadora, Portugal Rev Port Cardiol
More information2003 by the American College of Cardiology Foundation ISSN /03/$30.00
Journal of the American College of Cardiology Vol. 41, No. 4 Suppl S 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02963-7
More informationUNSTABLE angina pectoris is a transitory syndrome
Journal of Gerontology: MEDICAL SCIENCES 2003, Vol. 58A, No. 10, 927 933 Copyright 2003 by The Gerontological Society of America Review Article Treatment of Unstable Angina Pectoris/ Non-ST-Segment Elevation
More informationDirect Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI
Direct Thrombin Inhibitors for PCI Pharmacology: Role of Bivalirudin in High-Risk PCI Charles A. Simonton MD, FACC, FSCAI Sanger Clinic Medical Director Clinical Innovation and Research Carolinas Heart
More informationJournal of the American College of Cardiology Vol. 39, No. 10, by the American College of Cardiology Foundation ISSN /02/$22.
Journal of the American College of Cardiology Vol. 39, No. 10, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)01841-7
More informationA Report From the Second National Registry of Myocardial Infarction (NRMI-2)
1240 JACC Vol. 31, No. 6 Clinical Experience With Primary Percutaneous Transluminal Coronary Angioplasty Compared With Alteplase (Recombinant Tissue-Type Plasminogen Activator) in Patients With Acute Myocardial
More informationST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department
ST-segment Elevation Myocardial Infarction (STEMI): Optimal Antiplatelet and Anti-thrombotic Therapy in the Emergency Department decision-making. They have become the cornerstone of many ED protocols for
More informationDisclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None
Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationPATIENTS PRESENTING WITH AN
ORIGINAL CONTRIBUTION The TIMI Risk Score for Unstable Angina/Non ST Elevation MI A Method for Prognostication and Therapeutic Decision Making Elliott M. Antman, MD Marc Cohen, MD Peter J. L. M. Bernink,
More informationAntiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital
Antiplatelet and anticoagulant therapy for non-st-elevation acute coronary syndromes in a general hospital Authors G. Mason*, F. Wirth**, A. Cignarella***, R.G. Xuereb****, L.M. Azzopardi***** *Final Year
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationP atients with unstable angina or non-st elevation myocardial
36 CARDIOVASCULAR MEDICINE Cumulative risk assessment in unstable angina: clinical, electrocardiographic, autonomic, and biochemical markers S Kennon, C P Price, P G Mills, P K MacCallum, J Cooper, J Hooper,
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationTRANSPARENCY COMMITTEE OPINION. 2 April 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 April 2008 LOVENOX 6,000 IU anti-xa/0.6 ml, injectable solution (S.C.) in prefilled syringe Box of 2 (CIP: 364 690-3)
More informationJournal of the American College of Cardiology Vol. 41, No. 6, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02970-4
More informationCURRENT QUALITY IMPROVEment
ORIGINAL CONTRIBUTION Excess Dosing of Antiplatelet and Antithrombin Agents in the Treatment of Non ST-Segment Elevation Acute Coronary Syndromes Karen P. Alexander, MD Anita Y. Chen, MS Matthew T. Roe,
More informationTreatment strategies and risk stratification in acute coronary syndromes Damman, P.
UvA-DARE (Digital Academic Repository) Treatment strategies and risk stratification in acute coronary syndromes Damman, P. Link to publication Citation for published version (APA): Damman, P. (2013). Treatment
More informationKeywords Non ST-segment elevation ACS Antithrombotic therapy Glycoprotein IIb/IIIa inhibitor Tirofiban. Introduction
J Thromb Thrombolysis (2007) 24:241 246 DOI 10.1007/s19-007-0015-y Routine upstream versus selective down stream use of tirofiban in non-st elevation myocardial infarction patients scheduled for early
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 ANGIOX 250 mg, powder for concentrate for solution for injection or infusion by the intravenous route
More informationThe Role of Enoxaparin Across ACS Spectrum
SYP.ENO.16.08.01 The Role of Enoxaparin Across ACS Spectrum dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Optimum Anticoagulation in ACS patients : Summary from Guidelines Role of Enoxaparin in ACS Spectrum
More informationJournal of the American College of Cardiology Vol. 52, No. 22, by the American College of Cardiology Foundation ISSN /08/$34.
Journal of the American College of Cardiology Vol. 52, No. 22, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.021
More information- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -
MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationThe FRISC II ECG substudy
European Heart Journal (22) 23, 41 49 doi:1.153/euhj.21.2694, available online at http://www.idealibrary.com on ST depression in ECG at entry indicates severe coronary lesions and large benefits of an
More informationClinicalTrials.gov Identifier: NCT Sponsor/company: Sanofi-Aventis. Date: 08/02/ 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Sanofi-Aventis ClinicalTrials.gov
More informationThe Use of Low-Molecular-Weight Heparins in Acute Coronary Syndromes
ARTICLE The Use of Low-Molecular-Weight Heparins in Acute Coronary Syndromes Jennifer Spencer ABSTRACT Low-molecular-weight heparins are an attractive alternative to unfractionated heparin in many areas
More informationTwo-Year Follow-Up of Tirofiban-Based Management of Non-ST-Elevation Acute Coronary Syndrome A Single Center Study
Original Article Follow-Up of Tirofiban-Based NSTEACS Management Acta Cardiol Sin 2010;26:19 27 Coronary Heart Disease Two-Year Follow-Up of Tirofiban-Based Management of Non-ST-Elevation Acute Coronary
More informationCardiovascular risk and therapeutic benefit of coronary interventions for patients with unstable angina according to the troponin T status
European Heart Journal (2000) 21, 1159 1166 doi:10.1053/euhj.1999.1986, available online at http://www.idealibrary.com on Cardiovascular risk and therapeutic benefit of coronary interventions for patients
More informationAcute coronary syndromes refers to a spectrum of
Appropriate Use of Glycoprotein IIb/IIIa Blockade for Unstable Angina and Non ST Segment Elevation Myocardial Infarction Albert W. Chan, MD, MS, FRCP(C), and Sorin J. Brener, MD Objective: To review the
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationCase study #1 Evolving Concepts in Non-ST Elevation ACS (NSTE-ACS)
Case study #1 Evolving Concepts in Non-ST Elevation ACS (NSTE-ACS) Fernando Bátiz MD PGY-5 cardiology fellow Hospital Español Fernando Bátiz fernando_batiz@me.com Sex: Female Race: Caucasian Age: 79 years
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationJournal of the American College of Cardiology Vol. 38, No. 4, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 4, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01503-0 Acute
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationUnstable angina and NSTEMI
Issue date: March 2010 Unstable angina and NSTEMI The early management of unstable angina and non-st-segment-elevation myocardial infarction This guideline updates and replaces recommendations for the
More informationThe utility of fibrinolytic agents plus effective adjunctive
Randomized Comparison of Enoxaparin, a Low-Molecular-Weight Heparin, With Unfractionated Heparin Adjunctive to Recombinant Tissue Plasminogen Activator Thrombolysis and Aspirin Second Trial of Heparin
More informationSupplementary Table 1: Age, gender and treatment received in included studies
Supplementary Table 1: Age, gender and treatment received in included studies Study ID Mean age % male Therapies received Amlani 2010 [32] 62 80 Aspirin 99%, clopidogrel 99%, enoxaparin 17%, unfractionated
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationThe Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial
Journal of the American College of Cardiology Vol. 49, No. 23, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.12.049
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationCoronary plaque erosion: a clinical case. Dr. Giampaolo Niccoli, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy
Coronary plaque erosion: a clinical case, MD, PhD, FESC Institute of Cardiology Catholic University, Rome, Italy Coronary plaque erosion: a clinical case B.M. Age: 59 years Sex: female. Cardiological risk
More informationHeart disease is the leading cause of death
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS Christopher P. Cannon, MD,* ABSTRACT Acute coronary syndrome (ACS) is an important cause of morbidity and mortality in the US population
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More information